Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Emerging Infectious Diseases Année : 2022

Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali.

Résumé

To determine a demographic overview of orthopoxvirus seroprevalence, we tested blood samples collected during 2003-2019 from France (n = 4,876), Bolivia (n = 601), Laos (n = 657), and Mali (n = 255) for neutralizing antibodies against vaccinia virus. In addition, we tested 4,448 of the 4,876 samples from France for neutralizing antibodies against cowpox virus. We confirmed extensive cross-immunity between the 2 viruses. Seroprevalence of antibodies was <1% in Bolivia, <5% in Laos, and 17.25% in Mali. In France, we found low prevalence of neutralizing antibodies in persons who were unvaccinated and vaccinated for smallpox, suggesting immunosenescence occurred in vaccinated persons, and smallpox vaccination compliance declined before the end of compulsory vaccination. Our results suggest that populations in Europe, Africa, Asia, and South America are susceptible to orthopoxvirus infections, which might have precipitated the emergence of orthopoxvirus infections such as the 2022 spread of monkeypox in Europe.
Fichier principal
Vignette du fichier
22-1136.pdf (1.16 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03853175 , version 1 (12-10-2023)

Licence

Paternité

Identifiants

Citer

Léa Luciani, Nathanaël Lapidus, Abdennour Amroun, Alessandra Falchi, Chanthala Souksakhone, et al.. Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali.. Emerging Infectious Diseases, 2022, 28 (12), ⟨10.3201/eid2812.221136⟩. ⟨hal-03853175⟩
29 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More